| Identification | Back Directory | [Name]
Acetic acid, [[7,8-dihydro-5-[2-[[(Z)-(phenyl-3-pyridinylmethylene)amino]oxy]ethyl]-1-naphthalenyl]oxy]- (9CI) | [CAS]
153814-74-5 | [Synonyms]
Acetic acid, [[7,8-dihydro-5-[2-[[(Z)-(phenyl-3-pyridinylmethylene)amino]oxy]ethyl]-1-naphthalenyl]oxy]- (9CI) | [Molecular Formula]
C26H24N2O4 | [MOL File]
153814-74-5.mol | [Molecular Weight]
428.48 |
| Chemical Properties | Back Directory | [Boiling point ]
635.7±65.0 °C(Predicted) | [density ]
1.21±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
3.17±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
(Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig[1][2][3]. | [References]
[1] Hirata Y, et al. Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol. 2013;699(1-3):81-87. DOI:10.1016/j.ejphar.2012.11.045 [2] Kashiwagi H, et al. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice. J Pharmacol Exp Ther. 2015;353(2):269-278. DOI:10.1124/jpet.115.222612 [3] Kanayama S, et al. ONO-1301 Enhances in vitro Osteoblast Differentiation and in vivo Bone Formation Induced by Bone Morphogenetic Protein. Spine (Phila Pa 1976). 2018;43(11):E616-E624. DOI:10.1097/BRS.0000000000002439 |
|
|